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CC BY-NC-ND license (http://creativeAbstract Coronary heart disease (CHD) is a major cause of morbidity and mortality in devel-
oped countries. Metabolic syndrome (MetS) is associated with increased risk of CHD. Cardiac
rehabilitation is considered an effective intervention and a Class I indication in patients with
CHD. This study was designed to evaluate the effects of home-based, integrated cardiac reha-
bilitation (HBICR) of patients with CHD in modifiable risk-factor control and exercise capacity.
Sixty-four patients with CHD were investigated and randomized into intervention and control
groups. The intervention group received a HBICR containing medication use, exercise program,
smoking-cessation counseling, and education regarding risk factors, nutrition, and the neces-
sity of continuing the program, whereas the control group received traditional care. Baseline
and follow-up assessments at 3 months and 12 months, including body composition, metabolic
syndrome risk score, and biochemical tests were performed in all patients. Additionally, car-
diopulmonary function tests were also performed at baseline and 3-month follow-up assess-
ments. There was a significant between-group, within-group, and interaction effect found in
the MetS Z scores. Significant within-group effects were also observed in modified Adult Treat-
ment Panel III score, waist circumference, high-density lipoprotein, and low-densityeclare no conflicts of interest.
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268 J.-T. Chen et al.lipoprotein. However, several cardiopulmonary parameters did not differ significantly at 3-
month follow-up between the two groups, including peak VO2, peak heart rate, peak respira-
tory exchange ratio, anaerobic threshold VO2, heart-rate reserve, and heart-rate recovery af-
ter 1 min and after 2 min. Our results showed that HBICR exhibited significant positive effects
on modifiable risk-factor control in CHD patients.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Coronary heart disease (CHD) is a major cause of morbidity
and mortality in developed countries. Although CHD mor-
tality rates have declined over the past four decades, CHD
remains responsible for approximately one-third of all
deaths in individuals over age 35 [1]. According to the
Framingham Heart Study, several risk factors contribute to
CHD development, evolution, progression, and termina-
tion. Traditional modifiable risk factors that may
contribute to most CHD include tobacco use, dyslipidemia,
hypertension, diabetes, obesity, physical inactivity, and
low fitness. Metabolic syndrome (MetS) is characterized by
a group of cardiovascular risk factors, including hyperten-
sion, obesity, dyslipidemia, and insulin resistance, and
associated with increased risk of CHD in most populations
[2]. These risk factors tend to cluster together in patients
and substantially increase the hazard of development of
cardiovascular disease. Since its first definition, many
studies focused on whether MetS was associated with
increased risk of CHD and how to decrease mortality rates
from CHD, which principally involved reduction in risk
factors [3].
Effective management of CHD is multimodal and in-
cludes appropriate drug therapy, lifestyle modifications,
and cardiac rehabilitation (CR). Secondary prevention is
also emphasized and can be achieved by patient education,
exercise training, and self-care counseling and support [4].
Integrated cardiac care programs positively affect the
process of care, functional status, and quality of life for
CHD patients and reduce recurrence of myocardial infarc-
tion by nearly 20% over a median follow-up of 12 months
[5]. Many studies also reported a statistically significant
reduction in total and cardiac mortality by the effects of CR
[5,6]. Despite the recommendation for CR as an integral
component of care for CHD patients, most do not receive it.
Therefore, a randomized control trial was conducted by
an integrated care team with an out-hospital setting and
home-based CR program for patients with CHD. The original
study was undertaken to determine whether the integrated
care team could reduce CHD-related morbidity and mor-
tality as compared with use of traditional care methods.
Our ancillary study was designed to evaluate the probable
positive effects of the integrated care team, especially in
modifiable risk-factor control and exercise capacity.
Furthermore, we used a detailed survey for evaluation of
the treatment effect, including risk-factor control and
cardiopulmonary fitness.Materials and methods
Study design
The original study was a randomized controlled trial per-
formed in Kaohsiung Medical University Chung-Ho Memorial
Hospital. All patients hospitalized in the cardiac intensive
care unit and cardiovascular ward for CHD were screened
and admitted to the clinical trial from January 2011 to
January 2012. Patients were eligible if they suffered from
acute myocardial infarction or angina. The intervention
they received during hospitalization, such as percutaneous
transluminal coronary angioplasty (PTCA) and coronary ar-
tery bypass graft surgery (CABG), was also recorded. Pa-
tients were excluded if they had a history of pacemaker use
or heart transplantation, had any systemic diseases that
were limiting to exercise programs, or had worse short-
term prognosis. Patients also had to be able to attend
regular visits at an outpatient program after discharge.
During the recruitment period, 137 patients were exam-
ined. Seventy-five patients who met the inclusion criteria
were identified and randomly allocated with a two-to-one
ratio to the intervention or control group. Finally, 71 pa-
tients consented to participate in the study. The primary
outcome measures included death, non-fatal myocardial
infarction, recurrent angina, and emergency room visit or
readmission due to any cardiovascular-related diseases.
The secondary outcome measures were modifiable risk-
factor control and exercise capacity.Intervention
Participants randomized to the intervention group received
a home-based integrated cardiac rehabilitation (HBICR).
HBICR comprised evidence-based medical drug use, oral
instruction on the exercise program, smoking-cessation
counseling, and education regarding risk factors, nutri-
tion, and the necessity of continuing the program at home.
After enrollment, participants who entered the HBICR
group were trained on the program and instructed on how
to use the study equipment provided. The exercise program
was individualized, but based on a phase two CR program
approved by the American Heart Association. The main
exercise time was 30 min/day, with a 10-min warm up and a
10-min cool down at a frequency of 3 days/week and at an
intensity of 11 to 13 on the Borg scale of rate of perceived
exertion. Patients were allowed to choose activities
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was recommended. During exercise, a pedometer was
worn, and the data was recorded in an exercise diary. To
deliver the program, participants were telephoned each
week for 3 months at a scheduled time to review the pro-
gram content. Regarding risk-factor management and
medical adjustment, the participants consulted a cardiol-
ogist at baseline and after 1, 3, 6, and 12 months.
Participants in the control group received traditional
care and were not offered exercise education, but provided
medical adjustment by a cardiologist at baseline and after
1, 3, 6, and 12 months.
Angiographic studies
We used the cumulative coronary stenosis score (CCSS) to
estimate the total burden of luminal diameter affecting the
epicardial segments of the coronary arteries. The CCSS is an
arbitrary index that could represent the anatomic exten-
sion and severity of CHD. It was calculated by adding all
percent stenosis calculations in the angiography evaluation
[7].
Continuous metabolic syndrome risk score
The National Cholesterol Education Program adult treat-
ment panel III (ATP III) guidelines define the MetS as the
presence more than three of the following risk de-
terminants, and the Bureau of Health Promotion Adminis-
tration, Ministry of Health and Welfare in Taiwan modified
these determinants for people in Taiwan as: (1) increased
waist circumference (90 cm for men, 80 cm for women); (2)
elevated triglycerides of 150 mg/dL; (3) low high-density
lipoprotein (HDL) cholesterol (40 mg/dL for men, 50 mg/dL
for women); (4) hypertension (systolic blood pressure of
130 mmHg or diastolic pressure of 85 mmHg) or antihyper-
tensive medication use; and (5) impaired fasting glucose
(100 mg/dL). The MetS Z score used in our study was a
continuous gender-specific score of the five MetS variables
and accounted for variations in ATP III criteria [8,9]. The
equations used were Z score Z [(50HDL)/
14.1] þ [(triglycerides150)/81.0] þ [(fasting-plasma
glucose100)/11.3] þ [(waist circumference88)/
9.0] þ [(mean arterial pressure100)/9.1] for women and Z
score Z [(40HDL)/9.0] þ [(triglycerides150)/
81.0] þ [(fasting-plasma glucose100)/11.3] þ [(waist cir-
cumference102)/7.7] þ [(mean arterial pressure100)/
9.1] for men [7]. Additionally, a modified ATP III score was
also calculated as a sum of the criteria of metabolic syn-
drome as defined by the Bureau of Health Promotion
Administration, Ministry of Health and Welfare in Taiwan in
2007.
Anthropometry and respiratory function
Body height and weight were measured following standard
techniques, with the subjects in light clothes and without
shoes. Body height was determined to the nearest 0.5 cm,
and body weight was measured with a precision of 0.1 kg.
The body mass index (BMI) was calculated as body weight/
height2.Forced spirometry was assessed using a digital
computer-based spirometer (microQuark; COSMED, Rome,
Italy). Vital capacity and forced-expired volume in one
second were calculated from flow-volume curves. Maximal
voluntary ventilation (MVV) was directly estimated. The
highest values of at least three measurements were used.
Cardiopulmonary exercise test
All testing was performed on a calibrated
electromagnetically-braked cycle ergometer (Corival V2;
Lode BV, Groningen; Netherlands). During testing, patients
were seated in an upright position on the cycle with their
hands in a relaxed position on the handlebars. The exercise
testing on the ergometer was performed according to the
ramp-incremental protocol to either voluntary exhaustion
or inability to maintain a pedaling rate of 50 rpm [10].
Following a 4-min rest period, patients began pedaling on
the ergometer at 60 rpm at a work rate of zero load for
4 min. After reaching a steady rate at zero load, the testing
advanced to the ramp protocol. Throughout all power
outputs, patients were required to maintain a constant
pedaling rate of 60 rpm. Termination of testing followed
American College of Sports Medicine guidelines [11].
Expired gas was analyzed via open-circuit spirometry using
a gas analyzer (Meta-Max 3B; CORTEX Biophysik GmbH,
Leipzig, Germany) to determine oxygen uptake (VO2), car-
bon dioxide production, minute ventilation (VE), and res-
piratory exchange ratio (RER). Volume calibration and
calibration of gases by using standard gases were done
before each test. The patient wore a mask and breathed
room air though an attached 1-way directional valve sys-
tem. An electrocardiogram provided continuous monitoring
of heart rate (HR) and cardiac electrical activity. Some HR
parameters were calculated, including HR reserve (HRR),
HR recovery after 1 min (HHR1), and HR recovery after
2 min (HHR2). HRR was expressed in units of beats/min and
defined as the difference between a measured maximum
HR and resting HR. HR recovery (HHR1 and HHR 2) was
defined as the difference between HR at peak exercise and
1 or 2 min later. Left brachial artery systolic and diastolic
blood pressure were measured using a calibrated sphyg-
momanometer. Oxygen pulse (O2 pulse) in milliliters of
oxygen per beat (VO2/HR), exercise breathing reserve in
milliliters of gas per minute (MVVVEpeak), and ventilatory
reserve in percentage (VEpeak/MVV) were calculated.
Anaerobic threshold (AT) was determined using the V-slope
method [12]. Age-predicted maximal HR (HRmax) was
determined as (220 e age). The formula for those patients
taking beta-blocking medications was adjusted as
.85(220  age) to accommodate the HR-lowering effects of
this type of medication [13]. Resting measurements were
determined during the 4th-min rest period and unloaded
measurements during the 4th-min zero-workload period.
Peak values were the averages of values recorded during
the last 30 s of the test.
Outcome assessment
All participant baseline characteristics and clinical vari-
ables were measured during hospitalization, including age,
Table 1 Baseline characteristics of both groups.
Variables Intervention
(n Z 44)
Control
(n Z 20)
p
Male sex 39 (88.6%) 19 (95.0%) >0.999
Age (y) 56.8  7.7 53.7  10.2 0.130
Cumulative
coronary
stenosis score
1.83  0.92 1.76  1.14 0.259
Coronary heart
disease
0.838
One-vessel
disease
17 (38.6%) 9 (45.0%)
Two-vessel
disease
14 (31.8%) 5 (25.0%)
Three-vessel
disease
13 (29.6%) 6 (30.0%)
Acute coronary
syndrome
0.856
STEMI 23 (52.3%) 9 (45.0%)
NSTEMI 9 (20.4%) 5 (25.0%)
Unstable angina 12 (27.3%) 6 (30.0%)
Major invasive management
PTCA 38 (86.4%) 18 (90.0%) 0.417
CABG 6 (13.6%) 2 (10.0%) >0.999
Past history
Metabolic
syndrome
16 (36.4%) 6 (30.0%) 0.183
Diabetes mellitus 19 (43.2%) 6 (30.0%) 0.411
Hypertension 31 (70.5%) 11 (55.0%) 0.265
Smoking 29 (65.9%) 11 (55.0%) 0.419
Alcohol 15 (34.1%) 2 (10.0%) 0.066
Medication history
Antiplatelet
agents
43 (97.7%) 20 (100.0%) >0.999
Antihypertension
drugs
44 (100.0%) 20 (100.0%) >0.999
Oral antidiabetic
drugs
14 (31.8%) 4 (20.0%) 0.385
Statin agents 36 (81.8%) 18 (90.0%) 0.486
Values expressed as mean  SD, number or percentage.
CABG Z coronary artery bypass grafting; NSTEMI Z non-ST-
segment elevation myocardial infarction; PTCAZ percutaneous
transluminal coronary angioplasty; SD Z standard deviation;
STEMIZ ST-segment elevation myocardial infarction.
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ference, BMI, MetS Z score, blood pressure, medication use,
and tobacco- or alcohol-use habits. Biochemical and car-
diopulmonary exercise tests were also evaluated at
3 months after enrollment. At the 3-monthly visit,
biochemical variables (e.g., MetS Z score, waist circum-
ference, triglycerides, blood pressure, cholesterol, and
fasting-plasma glucose) were recorded, and cardiopulmo-
nary measurements (e.g., peak VO2, AT, peak and AT
workload, peak RER, peak HR, HRR, HHR1, HHR2, and
exercise-breathing reserve) were obtained, as well. More-
over, a long-term follow-up measuring changes in
biochemical variables was performed at the 12-month visit.
Statistical analysis
Descriptive statistics were calculated for demographic
variables. Chi-square and t tests were used to compare
differences between the two groups at baseline with regard
to categorical and continuous variables. For outcome vari-
ables, repeated-measures analysis of covariance models
was used to assess differences in baseline, 3-month, and
12-month follow-up between the two groups. A significance
level of p < 0.05 was used for all tests. All analyses were
conducted using SAS statistical software version 9.3 (SAS
Institute Inc., Cary, NC, USA).
Results
The study included sixty-four patients with CHD who un-
derwent baseline, 3-month, and 12-month assessments.
These participants were randomized into two groups of
intervention (nZ 44) and control (nZ 20). Table 1 displays
the background demographic and clinical characteristics of
the two sample groups. The mean age of the participants
was 56.8  7.7 and 53.7  10.2 years in the intervention
and control groups, respectively, and the majority of the
participants were men (90.6%). The baseline value of CCSS,
CHD classification, past history of MetS, hypertension or
diabetes, and major treatment for PTCA or CABG between
the two groups revealed no significant differences; there-
fore, patients in the two study groups were considered to
exhibit similar disease severity. Regarding past history and
lifestyle, 36.4% and 30.0% of patients in the intervention
and control group, respectively, had MetS, 70.5% and 55.0%
had hypertension, 43.2% and 30.0% had diabetes, 65.9% and
55.0% were current smokers, and 34.1% and 10.0% were
alcohol users. All of the baseline characteristics revealed
no statistically significant differences between the inter-
vention and control groups. The loss of follow-up rate at
the 12-month visit was 4.4% in the intervention group and
20.0% in the control group.
Modifiable risk factors of coronary heart disease
Risk factors of CHD and MetS are listed in Table 2. MetS Z
scores in the intervention group showed a progressive-
improvement trend from 0.99  3.93 at baseline,
1.74  3.57 at 3 months, and 2.26  3.83 at 12 months
(a negative number indicates lower risk). In contrast, the
MetS Z score of the control group revealed a less desirablepattern, from 1.04  3.79 (baseline) to 0.96  3.83
(12 months). Figure 1 depicts the difference in MetS Z score
in both groups at each follow-up assessment. There were
also statistically significant differences found in the de-
grees of change in the MetS Z scores at 12 months between
the intervention and control groups. Among the analysis of
covariance models for the adjusted analysis of MetS Z
scores, significant between-group effects, within-group
effects, and interaction effects were detected. Addition-
ally, statistically significant within-group effects were
observed in the modified ATP III score, waist circumfer-
ence, HDL, and LDL measurements. Furthermore, signifi-
cant interaction effects were also noted in modified ATP III
score and HDL measurements.
Table 2 Factors affecting metabolic syndrome changes over time between and within the study groups.
Intervention group Control group Between-group
effect
Within-group
effect
Interaction
effect
Baseline 3 month 12 month Baseline 3 month 12 month p p p
MetS Z score 0.99  3.93 1.74  3.57 2.26  3.83**,*** 1.04  3.79 0.96  3.52 0.96  3.83 0.045 0.030 0.038
mATP III score 2.93  1.37 2.66  1.33 1.81  1.40*** 2.3  1.37 2.65  1.50 2.73  0.96 0.453 0.003 0.001
BMI (kg/m2) 25.7  3.5 25.7  5.5 27.2  4.0*** 25.5  3.9 25.4  3.9 25.4  4.3 0.297 0.308 0.027
Waist (cm) 90.8  9.6 90.3  9.9 88.9  10.5*** 88.8  9.2 87.5  9.2 87.4  10.2 0.511 0.002 0.343
MAP (mmHg) 91.6  9.5 89.0  9.3 88.1  10.2 91.3  25.0 84.0  23.6 77.7  34.4*,*** 0.313 <0.001 0.009
HDL (mg/dL) 37.3  8.6 40.7  10.3 42.5  8.6*** 37.7  7.4 36.4  9.5 39.4  7.8 0.241 0.004 0.032
Triglyceride
(mg/dL)
149.1  90.9 141.2  84.9 155.5  20.1 129.3  85.6 246.0  496.8 218.5  269.8 0.221 0.128 0.067
FS (mg/dL) 127.5  39.2 121.6  46.2 117.4  34.8*** 117.3  37.1 116.1  44.1 111.9  27.8 0.636 0.184 0.871
LDL (mg/dL) 116.3  42.7 86.1  28.6 89.8  29.8*** 94.3  40.1 72.4  24.6 85.9  36.3 0.122 <0.001 0.485
HbA1c (%) 8.2  1.7 7.2  1.1 7.3  0.8*** 8.8  2.5 8.0  2.3 8.7  2.2 0.448 0.105 0.768
Values expressed as mean  SD.
* p < 0.05, statistical significance of the comparison of variables between the intervention and control groups (between-group comparison).
** p < 0.05, statistical significance of the comparison of change in variables at 12 months between the groups (between-group comparison).
*** p < 0.05, statistical significance of the comparison within the groups at the 12-month follow-up (within-group comparison).
BMI Z body mass index; FS Z fasting sugar; HbA1c Z glycated hemoglobin; HDL Z high-density lipoprotein; LDL Z low-density lipoprotein; MAP Z mean arterial pressure; mATP III
score Z modified ATP III score [The National Cholesterol Education Program (NCEP) adult treatment panel-III score]; MetS Z metabolic syndrome; SD Z standard deviation.
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Figure 1. Change trends in the metabolic syndrome Z score between the intervention and control groups.
272 J.-T. Chen et al.Cardiopulmonary measurements of the exercise
test
Results for the cardiopulmonary exercise test are presented
in Table 3. There were no statistically significant differ-
ences in all variables at baseline assessment between
groups. With regard to between-group effects, there were
no significant differences observed in several cardiopul-
monary parameters, including peak VO2, peak HR, peak
RER, peak workload, AT VO2, AT workload, HRR, HHR1, and
HHR2, after receiving the HBICR. Notably, statistically sig-
nificant within-group and interaction effects were observed
in the HHR2 and HRR of the control group at the 3-month
follow-up.
Discussion
According to our results, statistically significant improve-
ment was observed in risk-factor control of CHD patients
after HBICR, including MetS Z score, modified ATP III score,
and lipid profile. However, there was no significant differ-
ence noted in exercise capacity, such as peak VO2, between
groups. Conversely, HRR and HHR2 were found to improve
significantly in the control group. Several studies investi-
gated secondary prevention of CHD. CR was recommended
by the American College of Cardiology Foundation/Amer-
ican Heart Association for patients with diagnosis of acute
coronary syndrome or coronary artery disease, post-
percutaneous coronary intervention, or bypass surgery.
Comprehensive CR programs that include exercise, educa-
tion, behavior change, counseling, and facilitation of risk
reduction strategies improved physical health and
decreased subsequent morbidity and mortality in patients
with CHD [2,14]. In this study, we evaluated the effect of
HBICR on modifiable cardiac risk factors and cardiopulmo-
nary fitness in patients with CHD.
MetS is strongly associated with increased risk of CHD,
adverse cardiovascular outcomes, and all-cause andcardiovascular mortality. In the Scandinavian Simuvastatin
Survival Study [15], MetS was identified as a relatively
common condition in patients with stable CHD, affecting
almost a quarter of this European population. Furthermore,
Daly et al. [3] concluded that a metabolic profile should
form part of the risk assessment in all patients with CHD
and not just those who are obese or have diabetes.
Consequently, we used a continuous score (the MetS Z
score) rather than a series of dichotomous scores to
represent and detect overall metabolic changes and to
accurately measure the effects of our intervention.
One major finding in our study was that, compared with
the control group, the intervention group showed signifi-
cant improvement and treatment effects according to MetS
Z score at the 12-month follow-up. We also showed that,
compared to traditional care, there was a statistically sig-
nificant improvement in modified ATP III score and HDL
levels between groups. Our results study indicated that the
HBICR was adequate for obtaining significant health bene-
fits in CHD patients. Unfortunately, there was insufficient
data to definitively conclude presence of a significant gain
in cardiopulmonary fitness after HBICR. We also found that
changes in mean arterial pressure in the intervention group
also improved at the 12-month follow-up assessment, but
that the control group showed more significant improve-
ment relative to the intervention group. We speculated
that the effect on blood-pressure change might by influ-
enced by not only the CR, but also the adjustment of
antihypertension drugs during the follow-up period.
CR is a class I indication for CHD patients and should be
considered as an integral component of any cardiology
prevention-service continuum [16]. Aerobic capacity, usu-
ally measured as the peak VO2, was a strong predictor of
survival in cardiac patients. HRR and HHR were also used to
represent the chronotropic incompetence to exercise, ex-
ercise intolerance, and cardiovascular mortality [17]. In
previous studies, CR, including moderate-intensity exer-
cise, was beneficial in CHD patients in terms of improved
cardiopulmonary fitness and mortality prevention.
Table 3 Cardiopulmonary exercise-test measurements for the two groups.
Intervention Control Between-
group
effect
Within-
group
effect
Interaction
Baseline 3-month Baseline 3-month p p p
Vital capacity (L) 3.2  0.7 3.1  0.7* 3.5  0.8 3.6  0.9 0.028 0.456 0.162
FEV1 (L) 2.4  0.6 2.4  0.6* 2.7  0.8 2.9  0.8 0.027 0.028 0.086
FEV1/VC (%) 79.7  8.6 81.7  8.6 79.2  10.5 80.6  7.2 0.733 0.179 0.720
MVV (L/min) 87.4  27.9 88.8  25.4* 97.3  25.1 103.7  26.8 0.058 0.078 0.421
Peak SBP (mmHg) 152.4  14.3 151.5  17.7 147.8  20.9 149.8  22.3 0.435 0.885 0.446
Peak DBP (mmHg) 82.4  11.1 79.0  9.8 84.2  12.3 81.7  8.5 0.356 0.044 0.730
Peak workload (W) 86.6  32.2 89.0  31.8 97.6  37.6 106.2  41.6*** 0.129 0.003 0.086
Peak HR (bpm) 113.0  16.2 115.6  16.2 113.2  19.4 120.8  16.4*** 0.491 0.008 0.065
Peak VO2
(mL/kg/min)
15.1  5.4 14.8  4.7** 16.5  4.5 15.7  4.7 0.310 0.479 0.792
Peak O2 pulse
(mL/beat)
9.7  2.3 9.0  2.3 10.8  3.3 9.7  2.8 0.191 0.037 0.924
Peak VE (L/min) 44.5  13.3 45.4  13.9 42.3  11.0 46.7  13.0*** 0.886 0.009 0.067
Peak RER 1.3  0.3 1.4  0.3 1.2  0.2 1.4  0.3*** 0.829 0.010 0.171
AT VO2 (mL/min) 672.7  172 669.7  185*** 748.1  226 706.7  215*** 0.180 <0.001 0.176
AT VO2
(mL/kg/min)
8.8  3.2 9.5  3.5*** 9.7  2.5 9.7  2.9*** 0.499 <0.001 0.507
AT Workload (W) 59.5  134.3 44.9  18.3*** 50.3  15.6 54.5  19.9 0.007 0.055 0.693
AT/peak VO2 (%) 78.4  10.2 79.9  11.8 55.2  38.4 66.1  30.2 0.004 0.138 0.113
Peak HR/Maximal
HR (%)
69.1  9.8 71.3  9.8 74.6  28.2 72.8  10.5 0.247 0.863 0.678
HRR (bpm) 49.4  15.7 44.6  14.8 54.6  20.7 44.9  18.3**,*** 0.827 <0.001 0.012
HHR1 (bpm) 14.9  6.6 15.9  6.7 18.1  7.1 17.3  4.4 0.277 0.446 0.735
HHR2 (bpm) 22.6  8.2 23.9  8.8 23.7  6.6 27.2  6.9*** 0.604 0.006 0.022
EBR (L/min) 42.9  24.7 43.6  23.0* 53.4  22.6 57.1  21.8 0.032 0.288 0.716
Ventilatory
reserve (%)
54.6  19.0 53.8  17.8 46.5  13.7 46.4  11.67 0.052 0.739 0.791
Values expressed as mean  SD.
* p < 0.05, statistical significance of the comparison of variables between intervention and control groups.
** p < 0.05, statistical significance of the comparison of change in variables at 3 months between the groups.
*** p < 0.05, statistical significance of the comparison of variables within the groups at the 3-month follow-up.
AT Z anaerobic threshold; bpm Z beats per minute; EBR Z exercise-breathing reserve; FEV1 Z forced expired volume in 1 s;
HHR1 Z heart-rate recovery after 1 min [Z HRmax  HR1 min later]; HHR2Z heart-rate recovery after 2 min [ Z HRmax  HR2 min
later]; HRR Z heart-rate reserve [ Z HRmax  HRrest]; MVV Z maximal voluntary ventilation; RER Z respiratory exchange ratio;
SD Z standard deviation; VC Z vital capacity; VE Z minute ventilation; VO2 Z oxygen uptake.
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tides and pro-inflammatory cytokines also improved with
exercise training. Additionally, higher exercise intensity
elicited larger improvements in peak VO2 [16e19]. There
was no significant difference of peak VO2 at baseline be-
tween the two groups in our study, suggesting that their
initial fitness levels were similar. However, we also
observed no between-group or within-group differences in
the improvement of peak VO2 at the 3-month assessment;
therefore, we observed no evidence of an affect from
different treatments between HBICR and traditional care.
A delayed decrease in HHR following a maximal exercise
test is also a predictor of mortality in both healthy adults
and in those with CHD [20]. HHR is a simple and readily
available parameter for the assessment of autonomic tone
and is used in many studies as a mortality and prognosis
indicator. There is mounting evidence that support-
attenuated HHR after exercise is associated withdecreased vagal activity, significantly related to endothe-
lial dysfunction, and is a powerful predictor of overall
mortality in CHD [21]. Furthermore, abnormal HHR provides
additional prognostic information to the angiographic
severity of CHD [22]. Although the exact mechanisms by
which exercise reduces mortality are unclear, one hypoth-
esis cited the effect of exercise on autonomic tone. Endo-
thelial function plays a key role in determining the clinical
manifestations of established atherosclerotic lesions and
further cardiovascular events, which are suppressed by
increased sympathetic tone [21]. According to Huang et al.
[21], significant relationships exist between the extent of
HHR and endothelial function, and a delay in HHR may
predict endothelial dysfunction, additional cardiovascular
events, or increased mortality. Tiukinhoy et al. [23] also
demonstrated that exercised-based CR is associated with
significant improvements in HHR based on the effects on
autonomic tone. HHR is useful as an outcome measurement
274 J.-T. Chen et al.for stratifying the risks of patients after finishing a CR
program. Our study differed from conclusions reported in
previous studies, in that our results did not support the
notion that HBICR improves short-term exercise capacity.
Moreover, there were also no significant improvements in
HHR, HRR, or the rate of clinical events, such as mortality
and major coronary events in patients receiving HBICR.
According to our findings, we concluded that this was
perhaps caused by the inconsistent exercise content
administered in the out-hospital setting of our CR program.
Our novel finding was that we observed no significant linear
association between risk-factor control and cardiopulmo-
nary fitness in CHD patients.
CR cannot be regarded as an isolated form of therapy
and must be integrated with all aspects of treatment.
There is strong, consistent, and positive evidence for the
effectiveness of CR with exercise and lifestyle adjustments
as major components [16,19]. The treatment guidelines
prescribed by Achttien et al. [19] also concluded that
exercise-based CR is effective in all phases of CR, including
mobilization at an early stage in the clinical phase, aerobic
exercise, strength training, relaxation therapy during the
outpatient-rehabilitation phase, and the adoption and
monitoring of a physically active lifestyle after outpatient
rehabilitation. Interestingly, in a recently published
Cochrane systemic review, Dalal et al. [24] compared the
effect of home-based and supervised hospital-based CR in
adults with acute myocardial infarction, angina, or heart
failure, or who had undergone revascularization. Twelve
randomized controlled trials were included, with most of
the recruited patients classed as low risk for further events
after myocardial infarction or revascularization. Notably,
no difference was observed between the two types of CR
programs in terms of mortality, cardiac events, exercise
capacity, risk-factor control, and quality of life. Addition-
ally, treatment adherence was significantly superior with
home-based CR [24].
We speculated that home-based CR for patients with
CHD was a feasible form of training and appeared equally
effective at improving exercise capacity, optimizing daily
physical function, and minimizing the risk of recurrent
cardiac events as compared to hospital-based CR. Most
importantly, the exercise-training component was consis-
tently identified as a central element of CR, regardless of
whether the program was conducted with supervision. The
mechanisms associated with exercise-based CR remain un-
clear, but may be due to improved myocardial revascular-
ization, protection against fatal dysrhythmias, improved
cardiovascular risk-factor profile, improved cardiovascular
fitness, or increased patient surveillance [6,25].
There were some limitations to our study. First, the
sample size was small, involving referrals from only a single
cardiac care unit, and the number of female participants
was low. Although the patients included were blinded, both
the care providers and data collectors were not blinded to
the intervention, which may have influenced the behavior
and attitude of the care provider. Second, the lost follow-
up rate was relatively higher in the control group as
compared to the intervention group. Third, this study did
not evaluate the effects that a rehabilitation program has
on self-reported health-related quality of life, smoking-
behavior changes, and cost effectiveness. Finally, our datadid not capture other measurements that may have been of
relevance to the current analysis, such as compliance with
the home-exercise program.
Conclusion
Patients with CHD attending our HBICR program reported
positive effects on modifiable risk-factor control, and the
MetS Z score we used appeared to be a good indicator for
treatment effectiveness at follow-up. Peak VO2 and HHR
were simple and readily available parameters used as
strong predictors of cardiopulmonary fitness and survival of
CHD. Nevertheless, we found no evidence that adequate
control of CHD risk factors in CHD patients contributed to
decreased mortality and cardiac events between patients
participating in HBICR as compared to those undergoing
traditional care. More studies are needed to provide sup-
porting evidence for the application of this CR program,
especially concerning details pertaining to the exercise
components.
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